BioWorld
-
Athira brings in an $85M series B to treat Alzheimer’s
-
Today's news in brief
-
Dimerix’s lead candidate to enter global REMAP-CAP trial to treat COVID-19 ARDS
-
Beigene’s FDA-cleared BTK inhibitor Brukinsa approved in China
-
Supply shortages continue to threaten pandemic response
-
Data questions arise for two major COVID-19 studies
-
Prilenia raises $62.5M to fund new trials in HD, ALS
-
Nodthera’s $55M series B to advance inflammasome efforts
-
DHODH enzyme makes catalyst grist for Immunic, others in MS-plus
BioWorld MedTech
-
Update to ISO 14155 delayed, alignment with EU MDR remains uncertain
-
Wearable patch flow sensor for hydrocephalus shunt secures FDA breakthrough designation
-
Today's news in brief
-
Uromems raises $17.5M to advance development of its electronic artificial urinary sphincter
-
BioWorld MedTech’s Diagnostics Extra for June 4, 2020
-
BioWorld MedTech Patent Highlights: Week 22
-
Genscript seeks EUA for test that indicates immunity to COVID-19
-
FDA’s Stenzel says standards for molecular tests for SARS-CoV-2 a good approximation for NGS testing
-
Hesperos' Human-on-a-Chip system provides insight on immune response in COVID-19
BioWorld Asia
-
China’s pharma market to see slower growth, but increasing innovation
-
Edigene, Immunochina betting on allogeneic CAR T therapy in cancer collaboration
-
Chinese cell therapy developers adopt new approaches to stand out
-
Biopharma builds arsenal, launches showdown to squash COVID-19
-
Challenges posed to Chinese biotechs in post-pandemic era
-
WHO launches COVID-19 patent pool, backed by 35+ countries
-
News in brief
-
Optimistic Sorrento looking to have COVID-19 antibody ready by October
-
Australia’s Prescient Therapeutics develops next-gen CAR T therapies with UPenn universal immune receptor
